Advances in gene discovery for neurodevelopmental disorders have identified SCN2A dysfunction as a leading cause of infantile seizures, autism spectrum disorder, and intellectual disability. SCN2A encodes the neuronal sodium channel Na V 1.2. Functional assays demonstrate strong correlation between genotype and phenotype. This insight can help guide therapeutic decisions and raises the possibility that ligands that selectively enhance or diminish channel function may improve symptoms. The well-defined function of sodium channels makes SCN2A an important test case for investigating the neurobiology of neurodevelopmental disorders more generally. Here, we discuss the progress made, through the concerted efforts of a diverse group of academic and industry scientists as well as policy advocates, in understanding and treating SCN2A-related disorders.
20, *
Advances in gene discovery for neurodevelopmental disorders have identified SCN2A dysfunction as a leading cause of infantile seizures, autism spectrum disorder, and intellectual disability. SCN2A encodes the neuronal sodium channel Na V 1.2. Functional assays demonstrate strong correlation between genotype and phenotype. This insight can help guide therapeutic decisions and raises the possibility that ligands that selectively enhance or diminish channel function may improve symptoms. The well-defined function of sodium channels makes SCN2A an important test case for investigating the neurobiology of neurodevelopmental disorders more generally. Here, we discuss the progress made, through the concerted efforts of a diverse group of academic and industry scientists as well as policy advocates, in understanding and treating SCN2A-related disorders.
The Role of SCN2A in Neurodevelopmental Disorders
Our understanding of the genetic causes of neurodevelopmental disorders has progressed dramatically in the past decade, raising hope for better treatments by illuminating the biological mechanisms of disease. In that time, disruption of the gene SCN2A (see Glossary) has been identified as a prominent cause of a wide range of neurodevelopmental disorders, including autism spectrum disorder (ASD), intellectual disability (ID), and infantile-onset seizures (before the first year of life) of varying severity. Moreover, and notably, the consequences of disease-associated variants on protein function can predict the nature and severity of the resulting phenotype.
SCN2A encodes the neuronal voltage-gated sodium channel Na V 1.2, which is involved in the initiation and propagation of action potentials in a range of neuron classes. Critically, from a therapeutic perspective, ion channels such as Na V 1.2 are 'druggable' targets, and smallmolecule compounds can be developed to directly and selectively increase or decrease channel function as the basis for potential treatments. Thus, the well-defined biology describing Na V 1.2 function, the strong genotype-phenotype correlations found within a genetically welldefined patient population, and the channel's potential as a target for therapeutics all make SCN2A a leading candidate for focused efforts to understanding and treating neurodevelopmental disorders. Following an SCN2A-dedicated workshop organized by the Simons Foundation Autism Research Initiative (SFARI) that convened academic scientists, representatives from biotechnology and pharmaceutical companies, as well as funders and family advocacy organizations, we summarize the current state of research, future directions, and consider potential opportunities and challenges in the Na V 1.2 field.
Highlights
Dysfunction in SCN2A has been recently recognized as a major cause of neurodevelopmental disorders (NDDs), including epilepsy, intellectual disability (ID), and autism spectrum disorder (ASD).
SCN2A encodes a neuronal sodium channel, Na V 1.2. In contrast to many other NDD-linked genes, there is a wellestablished body of literature on sodium channel function and dysfunction.
Loss of Na V 1.2 function contributes to ASD and ID, whereas gain of function contributes to early onset epilepsy. Such strong and bidirectional genotype-phenotype correlation is rare in brain disorders.
Sodium channel function can be enhanced or suppressed using pharmacology. This may allow for future, targeted treatment of SCN2A-associated disorders.
The neuropathophysiology revealed by investigating SCN2A may provide insight into the underlying biology of NDDs more generally.
